FDA rejects Novo Nordisk’s once-weekly insulin after questioning risks
Novo Nordisk’s once-weekly insulin has been turned down by the FDA, and the Danish pharma likely won’t be refiling until next year.
The FDA rejection …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
